Skip to main content

Monopar Therapeutics

corporate_fare Company Profile

Monopar Therapeutics

MNPR·NASDAQ·Life Sciences·CIK 0001645469

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing a treatment for Wilson disease and new radiopharmaceuticals for oncology. The company's Wilson disease product candidate is ALXN1840, an investigational once-daily, oral medicine in late-stage development. ALXN1840 (tiomolybdate choline) is designed to treat Wilson disease, a rare genetic condition affecting approximately 1 in 30,000 live births in the U.S., where the body accumulates toxic copper levels. There are an estimated 10,000 Wilson disease patients in the U.S., with about 5,000 currently diagnosed and treated. ALXN1840 has received Orphan Drug Designation in the U.S. and the EU, and Fast Track designation from the FDA. Monopar also has radiopharmaceutical programs targeting advanced cancers that express urokinase plasminogen activator receptor (uPAR). These include MNPR-101-Zr, which is in Phase 1 for imaging advanced cancers, and MNPR-101-Lu, which is in Phase 1a, and MNPR-101-Ac, which is in late preclinical-stage, both for the treatment of advanced cancers. The company builds its drug development pipeline through internal efforts and by licensing late preclinical- and clinical-stage therapeutics.

Monopar Therapeutics (NASDAQ:MNPR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for MNPR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for MNPR spans 8-K, 10-Q, DEF 14A, 10-K.

Recent high-impact activity:

  • Monopar Posts $6.2M Q3 Loss, $129.4M Cash, NDA Submission Weeks Away
  • Monopar Q3 Loss Widens to $6.2M as R&D Spend Jumps; $129.4M Cash Lasts to March 2028
  • Monopar Q2 2026: Cash Runway Through 2027, Rolling NDA Submission Underway
  • Six Insiders Adopt 10b5-1 Trading Plans for Up to 91,889 Shares
  • Monopar Posts Wider Q2 Loss, Insider Trading Plans Adopted Amid NDA Push

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$13.72M
Op. Cash Flow
-$12.2M
Operating Income
-$16.7M
Cash & Equivalents
$61.83M
Debt / Equity
0.00×
Shares Outstanding
6.69M sh
Source: 10-K · filed 2026-04-01 · accession 0001437749-26-010841

Short Interest & Short Volume

8.80 days to cover

FINRA reported short interest of 1,103,516 shares in MNPR as of the October 30, 2026 settlement, a 2.2% decrease from the prior period — about 8.8 days to cover at its recent average daily volume. On November 20, 2026, 74.1% of MNPR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,103,516 shares as of October 30, 2026
Change vs prior period▼ 2.2%
Days to cover8.80 at avg daily volume of 125,435
Daily short volume (FINRA facilities)74.1% of 60,367 shares on November 20, 2026
5-day average short volume64.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with M →
$67.35 -2.40% today
52-week range · as of 2026-11-12 $50.07 – $124.82
Market cap
$467.6M
Volume
132.6K (0.9× avg)
3-mo avg 148.7K
Live data · 2026-11-22 04:06 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MNPR - Latest Insights

MNPR
Nov 12, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $70.30
Real-time Price: $67.35 info
Change: -$2.95 (-4%) info
Market Cap: $467.597M info
MNPR
Nov 12, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $70.30
Real-time Price: $67.35 info
Change: -$2.95 (-4%) info
Market Cap: $467.597M info
MNPR
Aug 12, 2026, 9:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $115.19
Real-time Price: $67.35 info
Change: -$47.84 (-42%) info
Market Cap: $467.597M info
MNPR
Aug 12, 2026, 9:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $114.46
Real-time Price: $67.35 info
Change: -$47.11 (-41%) info
Market Cap: $467.597M info
MNPR
Aug 12, 2026, 9:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $115.19
Real-time Price: $67.35 info
Change: -$47.84 (-42%) info
Market Cap: $467.597M info
MNPR
Jul 22, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $113.57
Real-time Price: $67.35 info
Change: -$46.22 (-41%) info
Market Cap: $467.597M info
MNPR
Jun 30, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $94.56
Real-time Price: $67.35 info
Change: -$27.21 (-29%) info
Market Cap: $467.597M info
MNPR
Jun 30, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $94.56
Real-time Price: $67.35 info
Change: -$27.21 (-29%) info
Market Cap: $467.597M info
MNPR
Jun 26, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $87.68
Real-time Price: $67.35 info
Change: -$20.33 (-23%) info
Market Cap: $467.597M info
MNPR
Jun 26, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $87.68
Real-time Price: $67.35 info
Change: -$20.33 (-23%) info
Market Cap: $467.597M info
MNPR
Jun 23, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $68.66
Real-time Price: $67.35 info
Change: -$1.31 (-2%) info
Market Cap: $467.597M info
MNPR
Jun 01, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $65.04
Real-time Price: $67.35 info
Change: +$2.31 (+4%) info
Market Cap: $467.597M info
MNPR
May 19, 2026, 5:26 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $55.20
Real-time Price: $67.35 info
Change: +$12.15 (+22%) info
Market Cap: $467.597M info
MNPR
May 14, 2026, 2:00 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $58.91
Real-time Price: $67.35 info
Change: +$8.44 (+14%) info
Market Cap: $467.597M info
MNPR
Apr 30, 2026, 4:01 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $52.15
Real-time Price: $67.35 info
Change: +$15.20 (+29%) info
Market Cap: $467.597M info
MNPR
Apr 19, 2026, 7:00 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $56.60
Real-time Price: $67.35 info
Change: +$10.75 (+19%) info
Market Cap: $467.597M info
MNPR
Mar 27, 2026, 1:27 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $55.51
Real-time Price: $67.35 info
Change: +$11.84 (+21%) info
Market Cap: $467.597M info
MNPR
Mar 27, 2026, 1:00 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $55.67
Real-time Price: $67.35 info
Change: +$11.68 (+21%) info
Market Cap: $467.597M info
MNPR
Mar 02, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $54.81
Real-time Price: $67.35 info
Change: +$12.54 (+23%) info
Market Cap: $467.597M info
MNPR
Jan 30, 2026, 2:32 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $61.67
Real-time Price: $67.35 info
Change: +$5.68 (+9%) info
Market Cap: $467.597M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets